Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine

Cancer and Metastasis Reviews

Volumn 33, Issue 4, 2014, Pages 965-980

  Ryu, Soo Hyung ^a   Jang, Myoung Kuk ^b   Kim, Woo Jean ^c   Lee, Danbi ^d   Chung, Young Hwa ^d  

^a Inje University College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Cancer; Hepatocellular carcinoma; Metastasis; Metastatic tumor antigen; MTA1; Pegylated interferon; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; HEPATITIS B X PROTEIN; METASTATIC TUMOR ANTIGEN; METASTATIC TUMOR ANTIGEN 1; METASTATIC TUMOR ANTIGEN 2; METASTATIC TUMOR ANTIGEN 3; PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HEPATITIS B VIRUS X PROTEIN; HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SUSCEPTIBILITY; CHEMICAL STRUCTURE; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; COMPLICATION; GENETICS; LIVER NEOPLASMS; PATHOGENICITY; PATHOLOGY; PROGNOSIS; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS B VIRUS; HISTONE DEACETYLASES; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; PROGNOSIS; REPRESSOR PROTEINS; TRANS-ACTIVATORS;

EID: 84914158983     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9522-4     Document Type: Article

References (146)

1. Bosch, F. X., Ribes, J., Diaz, M., & Cleries, R. (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127(5 Suppl 1), S5–S16.
2. Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., et al. (2004). Hepatocellular carcinoma: recent trends in Japan. Gastroenterology, 127(5 Suppl 1), S17–S26.
3. El-serag, H. B. (2004). Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127(5 Suppl 1), S27–S34.
4. Chen, M. F., Hwang, T. L., Jeng, L. B., Jan, Y. Y., Wang, C. S., & Chou, F. F. (1989). Hepatic resection in 120 patients with hepatocellular carcinoma. Archives of Surgery, 124(9), 1025–1028.
5. Tsuzuki, T., Sugioka, A., Ueda, M., Iida, S., Kanai, T., Yoshii, H., et al. (1990). Hepatic resection for hepatocellular carcinoma. Surgery, 107(5), 511–520.
6. Nagorney, D. M., van Heerden, J. A., Ilstrup, D. M., & Adson, M. A. (1989). Primary hepatic malignancy: surgical management and determinants of survival. Surgery, 106(4), 740–748.
7. Llovet, J. M., Fuster, J., & Bruix, J. (1999). Intention-to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology, 30(6), 1434–1440.
8. Okada, S., Shimada, K., Yamamoto, J., Takayama, T., Kosuge, T., Yamasaki, S., et al. (1994). Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology, 106(6), 1618–1624.
9. Adachi, E., Maeda, T., Matsumata, T., Shirabe, K., Kinukawa, N., Sugimachi, K., et al. (1995). Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology, 108(3), 768–775.
10. Kumada, T., Nakano, S., Takeda, I., Sugiyama, K., Osada, T., Kiriyama, S., et al. (1997). Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology, 25(1), 87–92.
11. Mahoney, M. G., Simpson, A., Jost, M., Noe, M., Kari, C., Pepe, D., et al. (2002). Metastasis-associated protein (MTA) 1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene, 21(14), 2161–2170.
12. Hofer, M. D., Menke, A., Genze, F., Gierschik, P., & Giehl, K. (2004). Expression of MTA1 promotes motility and invasiveness of PNAC-1 pancreatic carcinoma cells. British Journal of Cancer, 90(2), 455–462.
13. Nicolson, G. L., Nawa, A., Toh, Y., Taniguchi, S., Nishimori, K., & Moustafa, A. (2003). Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer invasion, proliferation and nuclear regulation. Clinical and Experimental Metastasis, 20(1), 19–24.
14. Moon, H. E., Cheon, H., Chun, K. H., Lee, S. K., Kim, Y. S., Jung, B. K., et al. (2006). Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1alpha. Oncology Reports, 16(4), 929–935.
15. Yoo, Y. G., Kong, G., & Lee, M. O. (2006). Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO Journal, 25(6), 1231–1241.
16. Kim, S. H., Jeong, J. W., Park, J. A., Lee, J. W., Seo, J. H., Jung, B. K., et al. (2007). Regulation of the HIF-1alpha stability by histone deacetylases. Oncology Reports, 17(3), 647–651.
17. Jang, K. S., Paik, S. S., Chung, H. K., Oh, Y. H., & Kong, G. (2006). MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancer. Cancer Science, 97(5), 374–379.
18. Martin, M. D., Hilsenbeck, S. G., Mohsin, S. K., Hopp, T. A., Clark, G. M., Osborne, C. K., et al. (2006). Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Research and Treatment, 95(1), 7–12.
19. Hofer, M. D., Kuefer, R., Varambally, S., Li, H., Ma, J., Shapiro, G. I., et al. (2004). The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Research, 64(3), 825–829.
20. Toh, Y., Ohga, T., Endo, K., Adachi, E., Kusumoto, H., Haraguchi, M., et al. (2004). Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. International Journal of Cancer, 110(3), 362–367.
21. Balasenthil, S., Broaddus, R. R., & Kumar, R. (2006). Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Human Pathology, 37(6), 656–661.
22. Toh, Y., Oki, E., Oda, S., Tokunaga, E., Ohno, S., Maehara, Y., et al. (1997). Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. International Journal of Cancer, 74(4), 459–463.
23. Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Yukiue, H., Kaji, M., et al. (2002). Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer, 35(2), 149–154.
24. Kumar, R., Wang, R. A., & Bagheri-Yarmand, R. (2003). Emerging roles of MTA family members in human cancers. Seminars in Oncology, 30(5 suppl 16), 30–37.
25. Moon, W. S., Chang, K., & Tarnawski, A. S. (2004). Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-α. Human Pathology, 35(4), 424–429.
26. Hamatsu, T., Rikimaru, T., Yamashita, Y., Aishima, S., Tanaka, S., Shirabe, K., et al. (2003). The role of MTA1 gene expression in human hepatocellular carcinoma. Oncology Reports, 10(3), 599–604.
27. Ryu, S. H., Chung, Y. H., Lee, H., Kim, J. A., Shin, H. D., Min, H. J., et al. (2008). Metastatic tumor antigen 1 is closely associated with frequent post-operative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology, 47(3), 929–936.
28. Lee, H., Ryu, S. H., Hong, S. S., Seo, D. D., Min, H. J., Jang, M. K., et al. (2009). Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. Journal of Gastroenterology and Hepatology, 24(8), 1445–1450.
29. Lee, S. H., Chung, Y. H., Kim, J. A., Lee, D., Jin, Y. J., Shim, J. H., et al. (2011). Single nucleotide polymorphisms associated with metastatic tumor antigen 1 overexpression in patients with hepatocellular carcinoma. Liver International, 32(3), 457–466.
30. Jin, Y. J., Chung, Y. H., Kim, J. A., Park, W. H., Lee, D., Seo, D. D., et al. (2012). Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma. Digestive Diseases and Sciences, 57(11), 2917–2923.
31. Lee, D., Chung, Y. H., Kim, J. A., Park, W. H., Jin, Y. J., Shim, J. H., et al. (2013). Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer, 119(12), 2239–2246.
32. Yao, Y. L., & Yang, W. M. (2003). The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. Journal of Biological Chemistry, 278(43), 42560–42568.
33. Toh, Y., Pencil, S. D., & Nicolson, G. L. (1995). Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene, 159(1), 97–104.
34. Pencil, S. D., Toh, Y., & Nicolson, G. L. (1993). Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma. Breast Cancer Research and Treatment, 25(2), 165–174.
35. Toh, Y., & Nicolson, G. L. (2009). The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clinical and Experimental Metastasis, 26(3), 215–227.
36. Manavathi, B., & Kumar, R. (2007). Metastasis tumor antigens, an emerging family of multifaceted master coregulators. Journal of Biological Chemistry, 282(3), 1529–1533.
37. Nawa, A., Nishimori, K., Lin, P., Maki, Y., Moue, K., Sawada, H., et al. (2000). Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides. Journal of Cellular Biochemistry, 79(2), 202–212.
38. Singh, R. R., & Kumar, R. (2007). MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. Journal of Mammary Gland Biology and Neoplasia, 12(2–3), 115–125.
39. Pawson, T., & Schlessingert, J. (1993). SH2 and SH3 domains. Current Biology, 3(7), 434–442.
40. Bar-Sagi, D., Rotin, D., Batzer, A., Mandiyan, V., & Schlessinger, J. (1993). SH3 domains direct cellular localization of signaling molecules. Cell, 74(1), 83–91.
41. Weng, Z., Taylor, J. A., Turner, C. E., Brugge, J. S., & Seidel-Dugan, C. (1993). Detection of Src homology 3-binding proteins, including paxillin, in normal and v-Src-transformed Balb/c 3T3 cells. Journal of Biological Chemistry, 268(20), 14956–14963.
42. Toh, Y., Pencil, S. D., & Nicolson, G. L. (1994). A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. Journal of Biological Chemistry, 269(37), 22958–22963.
43. Kumar, R., Wang, R. A., Mazumdar, A., Talukder, A. H., Mandal, M., Yang, Z., et al. (2002). A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature, 418(6898), 654–657.
44. Li, W., Ma, L., Zhao, J., Liu, X., Li, Z., & Zhang, Y. (2009). Expression profile of MTA1 in adult mouse tissues. Tissue and Cell, 41(6), 390–399.
45. Liu, J., Xu, D., Wang, H., Zhang, Y., Chang, Y., Zhang, J., et al. (2014). The subcellular distribution and function of MTA1 in cancer differentiation. Oncotarget, 5(13), 5153–5164.
46. Nagaraj S. R., Shilpa P., Rachaiah K., Salimath B.P. (2013). Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma. Molecular Carcinogenesis, 2013 Nov 22. doi: 10.1002/mc.22104
47. Neuveut, C., Wei, Y., & Buendia, M. A. (2010). Mechanisms of HBV-related hepatocarcinogenesis. Journal of Hepatology, 52(4), 594–604.
48. Murakami, S. (2001). Hepatitis B virus X protein: a multifunctional viral regulator. Journal of Gastroenterology, 36(10), 651–660.
49. Zhang, X., Zhang, H., & Ye, L. (2006). Effects of hepatitis B virus X protein on the development of liver cancer. Journal of Laboratory and Clinical Medicine, 147(2), 58–66.
50. Yun, C., Um, H. R., Jin, Y. H., Wang, J. H., Lee, M. O., Park, S., et al. (2002). NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Letters, 184(1), 97–104.
51. Chan, D. W., & Ng, I. O. (2006). Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. Journal of Pathology, 208(3), 372–380.
52. Yoo, Y. G., Na, T. Y., Seo, H. W., Seong, J. K., Park, C. K., Shin, Y. K., et al. (2008). Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene, 27(24), 3405–3413.
53. Feitelson, M. A., & Lee, J. (2007). Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Letters, 252(2), 157–170.
54. Liu, B., Wen, X., Huang, C., & Wei, Y. (2013). Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. International Journal of Biochemistry and Cell Biology, 45(9), 1987–1996.
55. Wang, F., Zhou, H., Yang, Y., Xia, X., Sun, Q., Luo, J., et al. (2012). Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncology Reports, 27(4), 1170–1176.
56. Lara-Pezzi, E., Roche, S., Andrisani, O. M., Sánchez-Madrid, F., & López-Cabrera, M. (2001). The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene, 20(26), 3323–3331.
57. Lara-Pezzi, E., Majano, P. L., Yáñez-Mó, M., Gómez-Gonzalo, M., Carretero, M., Moreno-Otero, R., et al. (2001). Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. Journal of Hepatology, 34(3), 409–415.
58. Lara-Pezzi, E., Gómez-Gaviro, M. V., Gálvez, B. G., Mira, E., Iñiguez, M. A., Fresno, M., et al. (2002). The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. Journal of Clinical Investigation, 110(12), 1831–1838.
59. Chung, T. W., Lee, Y. C., & Kim, C. H. (2004). Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB Journal, 18(10), 1123–1125.
60. Yu, F. L., Liu, H. J., Lee, J. W., Liao, M. H., & Shih, W. L. (2005). Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. Journal of Hepatology, 42(4), 520–527.
61. Ou, D. P., Tao, Y. M., Chang, Z. G., Tang, F. Q., & Yang, L. Y. (2006). Hepatocellular carcinoma cells containing hepatitis B virus X protein have enhanced invasive potential conditionally. Digestive and Liver Disease, 38(4), 262–267.
62. Ou, D. P., Tao, Y. M., Tang, F. Q., & Yang, L. Y. (2007). The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. International Journal of Cancer, 120(6), 1208–1214.
63. Zhang, X., Liu, S., Hu, T., Liu, S., He, Y., & Sun, S. (2009). Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology, 50(2), 490–499.
64. Manavathi, B., Singh, K., & Kumar, R. (2007). MTA family of coregulators in nuclear receptor biology and pathology. Nuclear Receptor Signaling, 5, e010.
65. Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, R. D., Xia, W., Hung, M. C., Sarin, S. K., et al. (2010). NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene, 29(8), 1179–1189.
66. Jung, J. K., Park, S. H., & Jang, K. L. (2010). Hepatitis B virus X protein overcomes the growth-inhibitory potential of retinoic acid by downregulating retinoic acid receptor-beta2 expression via DNA methylation. Journal of General Virology, 91(Pt 2), 493–500.
67. Park, I. Y., Sohn, B. H., Yu, E., Suh, D. J., Chung, Y. H., Lee, J. H., et al. (2007). Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology, 132(4), 1476–1494.
68. Lee, M. H., Na, H., Na, T. Y., Shin, Y. K., Seong, J. K., & Lee, M. O. (2012). Epigenetic control of metastasis-associated protein 1 gene expression by hepatitis B virus X protein during hepatocarcinogenesis. Oncogenesis, 1, e25.
69. Reddy, S. D., Pakala, S. B., Ohshiro, K., Rayala, S. K., & Kumar, R. (2009). MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Research, 69(14), 5639–5642.
70. Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, D. R., Martin, E., Murad, F., & Kumar, R. (2010). Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. Journal of Biological Chemistry, 285(10), 6980–6986.
71. Aboobaker, A. A., Tomancak, P., Patel, N., Rubin, G. M., & Lai, E. C. (2005). Drosophila microRNAs exhibit diverse spatial expression patterns during embryonic development. Proceedings of the National Academy of Sciences of the United States of America, 102(50), 18017–18022.
72. Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065–7070.
73. Makeyev, E. V., & Maniatis, T. (2008). Multilevel regulation of gene expression by microRNAs. Science, 319(5871), 1789–1790.
74. Behm-Ansmant, I., Rehwinkel, J., & Izaurralde, E. (2006). MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harbor Symposia on Quantitative Biology, 71, 523–530.
75. Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 682–688.
76. Reddy, S. D., Ohshiro, K., Rayala, S. K., & Kumar, R. (2008). MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Research, 68(20), 8195–8200.
77. Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., et al. (2008). microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Research, 68(10), 3566–3572.
78. Li, S., Tian, H., Yue, W., Li, L., Gao, C., Si, L., et al. (2013). Down-regulation of MTA1 protein leads to the inhibition of migration, invasion, and angiogenesis of non-small-cell lung cancer cell line. Acta Biochimica et Biophysica Sinica, 45(2), 115–122.
79. Mazure, N. M., Brahimi-Horn, M. C., Berta, M. A., Benizri, E., Bilton, R. L., Dayan, F., et al. (2004). HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochemical Pharmacology, 68(6), 971–980.
80. Bruick, R. K., & McKnight, S. L. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 294(5545), 1337–1340.
81. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O’Rourke, J., Mole, D. R., et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107(1), 43–54.
82. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3(10), 721–732.
83. Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., et al. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell, 111(5), 709–720.
84. Côté, J., Quinn, J., Workman, J. L., & Peterson, C. L. (1994). Stimulation of GAL4 derivative binding to nucleosomal DNA by the yeast SWI/SNF complex. Science, 265(5168), 53–60.
85. Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E., & Green, M. R. (1994). Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature, 370(6489), 477–481.
86. Tsukiyama, T., & Wu, C. (1995). Purification and properties of an ATP-dependent nucleosome remodeling factor. Cell, 83(6), 1011–1020.
87. Cairns, B. R., Lorch, Y., Li, Y., Zhang, M., Lacomis, L., Erdjument-Bromage, H., et al. (1996). RSC, an essential, abundant chromatin-remodeling complex. Cell, 87(7), 1249–1260.
88. Wang, W., Chi, T., Xue, Y., Zhou, S., Kuo, A., & Crabtree, G. R. (1998). Architectural DNA binding by a high-mobility-group/kinesin-like subunit in mammalian SWI/SNF-related complexes. Proceedings of the National Academy of Sciences of the United States of America, 95(2), 492–498.
89. Varga-Weisz, P. D., Wilm, M., Bonte, E., Dumas, K., Mann, M., & Becker, P. B. (1997). Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature, 388(6642), 598–602.
90. Xue, Y., Wong, J., Moreno, G. T., Young, M. K., Côté, J., & Wang, W. (1998). NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Molecular Cell, 2(6), 851–861.
91. Nair, S. S., Bommana, A., Bethony, J. M., Lyon, A. J., Ohshiro, K., Pakala, S. B., et al. (2011). The metastasis-associated protein-1 gene encodes a host permissive factor for schistosomiasis, a leading global cause of inflammation and cancer. Hepatology, 54(1), 285–295.
92. Ghanta, K. S., Pakala, S. B., Reddy, S. D., Li, D. Q., Nair, S. S., & Kumar, R. (2011). MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. Journal of Biological Chemistry, 286(9), 7132–7138.
93. Pakala, S. B., Bui-Nguyen, T. M., Reddy, S. D., Li, D. Q., Peng, S., Rayala, S. K., et al. (2010). Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. Journal of Biological Chemistry, 285(31), 23590–23597.
94. Pakala, S. B., Reddy, S. D., Bui-Nguyen, T. M., Rangparia, S. S., Bommana, A., & Kumar, R. (2010). MTA1 coregulator regulates LPS response via MyD88-dependent signaling. Journal of Biological Chemistry, 285(43), 32787–32792.
95. Li, D. Q., Pakala, S. B., Reddy, S. D., Ohshiro, K., Peng, S. H., Lian, Y., et al. (2010). Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. Journal of Biological Chemistry, 285(13), 10044–10052.
96. Van Rechem, C., Boulay, G., Pinte, S., Stankovic-Valentin, N., Guérardel, C., & Leprince, D. (2010). Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Molecular and Cellular Biology, 30(16), 4045–4059.
97. Wales, M. M., Biel, M. A., el Deiry, W., Nelkin, B. D., Issa, J. P., Cavenee, W. K., et al. (1995). p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine, 1(6), 570–577.
98. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75(4), 817–825.
99. Vitari, A. C., Leong, K. G., Newton, K., Yee, C., O’Rourke, K., Liu, J., et al. (2011). COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature, 474(7351), 403–406.
100. Migliorini, D., Bogaerts, S., Defever, D., Vyas, R., Denecker, G., Radaelli, E., et al. (2011). Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. Journal of Clinical Investigation, 121(4), 1329–1343.
101. Li, D. Q., Ohshiro, K., Reddy, S. D., Pakala, S. B., Lee, M. H., Zhang, Y., et al. (2009). E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proceedings of the National Academy of Sciences of the United States of America, 106(41), 17493–17498.
102. Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature, 408(6810), 377–381.
103. Ohshiro, K., Rayala, S. K., Wigerup, C., Pakala, S. B., Natha, R. S., Gururaj, A. E., et al. (2010). Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator. EMBO Reports, 11(9), 691–697.
104. Denslow, S. A., & Wade, P. A. (2007). The human Mi-2/NuRD complex and gene regulation. Oncogene, 26(37), 5433–5438.
105. Mazumdar, A., Wang, R. A., Mishra, S. K., Adam, L., Bagheri-Yarmand, R., Mandal, M., et al. (2001). Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology, 3(1), 30–37.
106. Hay, E. D. (1995). An overview of epithelio-mesenchymal transformation. Acta Anatomica, 154(1), 8–20.
107. Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology, 15(3), 178–196.
108. Medici, D., & Kalluri, R. (2012). Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Seminars in Cancer Biology, 22(5–6), 379–384.
109. van Meeteren, L. A., & ten Dijke, P. (2012). Regulation of endothelial cell plasticity by TGF-β. Cell and Tissue Research, 347(1), 177–186.
110. Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007). Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research, 67(21), 10123–10128.
111. Lee, S. W., Won, J. Y., Kim, W. J., Lee, J., Kim, K. H., Youn, S. W., et al. (2013). Snail as a potential target molecule in cardiac fibrosis: paracrine action of endothelial cells on fibroblasts through snail and CTGF axis. Molecular Therapy, 21(9), 1767–1777.
112. Medici, D., Shore, E. M., Lounev, V. Y., Kaplan, F. S., Kalluri, R., & Olsen, B. R. (2010). Conversion of vascular endothelial cells into multipotent stem-like cells. Nature Medicine, 16(12), 1400–1406.
113. Wong, L. L., Chang, C. F., Koay, E. S., & Zhang, D. (2009). Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression. International Journal of Oncology, 34(5), 1291–1301.
114. Kim, R., Arihiro, K., Emi, M., Tanabe, K., & Osaki, A. (2006). Potential role of HER-2; in primary breast tumor with bone metastasis. Oncology Reports, 15(6), 1477–1484.
115. Jiang, W. G., Lloyds, D., Puntis, M. C., Nakamura, T., & Hallett, M. B. (1993). Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor. Clinical and Experimental Metastasis, 11(3), 235–242.
116. Jiang, W., Hiscox, S., Matsumoto, K., & Nakamura, T. (1999). Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Critical Reviews in Oncology/Hematology, 29(3), 209–248.
117. Stoker, M., & Perryman, M. (1985). An epithelial scatter factor released by embryo fibroblasts. Journal of Cell Science, 77, 209–223.
118. Savagner, P., Yamada, K. M., & Thiery, J. P. (1997). The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. Journal of Cell Biology, 137(6), 1403–1419.
119. Grotegut, S., von Schweinitz, D., Christofori, G., & Lehembre, F. (2006). Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO Journal, 25(15), 3534–3545.
120. Hiscox, S., & Jiang, W. G. (1999). Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochemical and Biophysical Research Communications, 261(2), 406–411.
121. Pakala, S. B., Singh, K., Reddy, S. D., Ohshiro, K., Li, D. Q., Mishra, L., et al. (2011). TGF-β1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene, 30(19), 2230–2241.
122. Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2(6), 442–454.
123. Dannenmann, C., Shabani, N., Friese, K., Jeschke, U., Mylonas, I., & Brüning, A. (2008). The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biology and Therapy, 7(9), 1460–1467.
124. Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., et al. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nature Cell Biology, 2(2), 84–89.
125. Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9(4), 265–273.
126. Moon, E. J., Jeong, C. H., Jeong, J. W., Kim, K. R., Yu, D. Y., Murakami, S., et al. (2004). Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1α. FASEB Journal, 18(2), 382–384.
127. Zhang, X. Y., DeSalle, L. M., Patel, J. H., Capobianco, A. J., Yu, D., Thomas-Tikhonenko, A., et al. (2005). Metastasis-associated protein I (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proceedings of the National Academy of Sciences of the United States of America, 102(39), 13968–13973.
128. Terradillos, O., Billet, O., Renard, C. A., Levy, R., Molina, T., Briand, P., et al. (1997). The hepatitis B virus X gene potentiates c-MYC induced liver oncogenesis in transgenic mice. Oncogene, 14(4), 395–404.
129. Ou, D. P., Tao, Y. M., Tang, F. Q., & Yang, L. Y. (2007). The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. International Journal of Cancer, 120(6), 1208–1214.
130. Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes and Development, 13(15), 1924–1935.
131. Park, N. H., Song, I. H., & Chung, Y. H. (2006). Chronic hepatitis B in hepatocarcinogenesis. Postgraduate Medical Journal, 82(970), 507–51.
132. Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998). Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 28(1), 68–77.
133. Pang, R., & Poon, R. T. (2006). Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Letters, 242(2), 151–167.
134. Song, B. C., Chung, Y. H., Kim, J. A., Lee, H. C., Yoon, H. K., Sung, K. B., et al. (2001). Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer, 91(12), 2386–2393.
135. Li, H., Sun, L., Xu, Y., Li, Z., Luo, W., Tang, Z., et al. (2013). Overexpression of MTA3 correlates with tumor progression in non-small cell lung cancer. Plos One, 8(6), 1–8.
136. Zhang, H., Stephens, L. C., & Kumar, R. (2006). Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clinical Cancer Research, 12(5), 1479–1486.
137. Dong, H., Guo, H., Xie, L., Wang, G., Zhong, X., Khoury, T., et al. (2013). The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. PloS One, 8(5), e62986.
138. Chu, H., Chen, X., Wang, H., Du, Y., Wang, Y., Zang, W., et al. (2014). MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. Tumour Biology, 35(4), 3487–3494.
139. Zhong, J. H., Ma, L., & Li, L. Q. (2014). Postoperative therapy options for hepatocellular carcinoma. Scandivian Journal of Gastroenterology, 49(6), 649–661.
140. Shin, J. W., & Chung, Y. H. (2013). Molecular targeted therapy for hepatocellular carcinoma: current and future. World Journal of Gastroenterology, 19(37), 6144–6155.
141. Ikeda, K., Saitoh, S., Suzuki, Y., Kobayashi, M., Tsubota, A., Fukuda, M., et al. (1998). Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer, 82(5), 827–835.
142. Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., et al. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group Inhibition of Hepatocarcinogenesis by Interferon Therapy. Annals of Internal Medicine, 131(3), 174–181.
143. Sun, H. C., Tang, Z. Y., Wang, L., Qin, L. X., Ma, Z. C., Ye, Q. H., et al. (2006). Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. Journal of Cancer Research and Clinical Oncology, 132(7), 458–465.
144. Kudo, M. (2008). Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology, 75(suppl 1), 30–41.
145. Zeisberg, M., Yang, C., Martino, M., Duncan, M. B., Rieder, F., Tanjore, H., et al. (2007). Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. Journal of Biological Chemistry, 282(32), 23337–23347.
146. Kim, K. H., Lee, W. R., Kang, Y. N., Chang, Y. C., & Park, K. K. (2014). Inhibitory effect of nuclear factor-κB decoy oligodeoxynucleotide on liver fibrosis through regulation of the epithelial-mesenchymal transition. Human Gene Therapy, 25(8), 721–729.